Stimulation of Wnt signaling in the tumor microenvironment either by ectopic expression of Wnt3a in HMCLs [54] or by systemic administration of Wnt3a, GSK3-inhibitors [56] or an anti-DKK1 monoclonal antibody (mAb) [92, 93] was found to increase osteoblast numbers, enhance bone formation, and prevent the development of osteolytic lesions. This evidence concerns the gene WNT3A and neoplasm.